Yosipovitch, Gil
Lio, Peter
Legat, Franz J.
Chovatiya, Raj
Deleuran, Mette
Pierce, Evangeline
Casillas, Marta
Ding, Yuxin
Yang, Fan E.
Bardolet, Laia
Ständer, Sonja
Clinical trials referenced in this document:
Documents that mention this clinical trial
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01199-9
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
https://doi.org/10.1007/s13555-024-01225-w
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
https://doi.org/10.1007/s13555-024-01226-9
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
Documents that mention this clinical trial
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
https://doi.org/10.1007/s13555-024-01225-w
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
https://doi.org/10.1007/s13555-024-01226-9
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
Article History
Received: 8 April 2024
Accepted: 27 June 2024
First Online: 13 July 2024
Declarations
:
: Gil Yosipovitch reports participation as a consultant and board member for Sanofi, Regeneron, Pfizer, Galderma, Novartis, Eli Lilly, Abbvie, Kiniksa, Trevi, Pierre Gabre, Leo, Escient. Celldex, Bellus, Research support Pfizer, Sanofi Regeneron, Leo, Eli Lilly, Kiniksa, Novartis, Escient, Bellus, Galderma, Celldex. Peter A. Lio has received grants as an investigator, honoraria for lecturing, and/or consulting fees from AbbVie, Arcutis, Almirall, Alphyn, Amyris, ASLAN, AOBiome, Bristol-Myers Squibb, Castle Biosciences, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Hyphens Pharma, Incyte, Janssen, LEO Pharma, La Roche-Posay, Merck, Micreos, Pfizer, Pierre-Fabre, Regeneron/Sanofi-Genzyme, and UCB. Franz J. Legat reports participation on Advisory Boards for Almirall, Celgene, Eli Lilly, Galderma, Menlo Therapeutics, Novartis, Pfizer, Trevi Therapeutics, and Vifor Pharma. Raj Chovatiya has served as an advisory board member, consultant, and/or speaker with personal fees for AbbVie, Apogee, Arcutis, Argenx, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, Galderma, Genentech, Incyte, LEO Pharma, L’Oréal, Novan, Inc., Pfizer Inc., Regeneron, Sanofi, and UCB. Mette Deleuran has served as a consultant, advisory board member, and/or speaker for Pfizer Inc., AbbVie, Eli Lilly and Company, LEO Pharma, Regeneron, Sanofi-Genzyme, Novartis, Pierre Fabre, Arena Pharmaceuticals, Incyte, ASLAN Pharmaceuticals, Numab, and Kymab. Laia Bardolet is an employee of Almirall. Marta Casillas, Yuxin Ding, Evangeline Pierce, and Fan E. Yang are employees and shareholders of Eli Lilly and Company. All authors meet the International Committee of Medical Journal Editors criteria for authorship for this article and have given their approval for this version to be published.
: Informed consent was obtained from all patients before study procedures were initiated. For patients considered to be minors, the written consent of the parent or legal guardian, as well as the assent of the minor, was obtained. Both studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.